ProStrakan Secures Offer From Japan's Kyowa Hakko, But Analysts Say Too Low
This article was originally published in PharmAsia News
Executive Summary
Three months after putting itself up for sale, U.K.-based specialty pharma firm ProStrakan Group PLC on Feb. 21 announced a cash offer from Japan's Kyowa Hakko Kirin Co. Ltd. The 130 pence-per-share deal values the company at about £292 million ($475 million)